We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Salivary Gland Needle Biopsy Technique Eases Diagnosis of Early Parkinson's Disease

By LabMedica International staff writers
Posted on 08 Feb 2016
A recent paper assessed the potential value of submandibular salivary gland biopsies for early Parkinson's disease (PD) and suggested that the technique might eventually emerge as a gold standard for biomarker studies short of autopsy confirmation.

While autopsy and advanced PD studies have suggested that the submandibular gland was an important biopsy site, there have been few, if any, studies in early PD. More...
Therefore, investigators at the Mayo Clinic (Phoenix, AZ, USA) performed transcutaneous needle core biopsies of the submandibular gland on 25 early PD (duration less than five years) patients and 10 controls. The biopsies were done as an office procedure, and the tissues were stained for phosphorylated alpha-synuclein. Only nerve element staining was considered positive.

Results revealed that submandibular gland needle biopsies identified phosphorylated alpha-synuclein staining in 74% (14/19) of early PD subjects and two of nine (22%) control subjects. False positives may be true false positives or may represent very early, asymptomatic PD.

“This is the first study demonstrating the value of testing a portion of the submandibular gland to diagnose a living person with early Parkinson's disease. Making a better diagnosis in living patients is a big step forward in our effort to understand and better treat patients," said first author Dr. Charles Adler, professor of neurology at the Mayo Clinic. This finding, in patients with early Parkinson’s disease, may be of great use since accuracy of diagnosis in patients with early disease is not nearly as good as in those having the disease for more than 10 years."

The study was published in the January 22, 2016, online edition of the journal Movement Disorders.

Related Links:

Mayo Clinic



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.